flavoxate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1175	15301-69-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: urispas flavoxate flavoxate hydrochloride flavoxate HCl	A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. Molecular weight: 391.47 Formula: C24H25NO4 CLOGP: 4.97 LIPINSKI: 0 HAC: 5 HDO: 0 TPSA: 55.84 ALOGS: -4.41 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

urispas
flavoxate
flavoxate hydrochloride
flavoxate HCl

A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.

Molecular weight: 391.47
Formula: C24H25NO4
CLOGP: 4.97
LIPINSKI: 0
HAC: 5
HDO: 0
TPSA: 55.84
ALOGS: -4.41
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	6.60 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Jan. 15, 1970	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Soft tissue disorder	410.88	59.79	78	2089	4344	63482511
Pneumonia viral	276.13	59.79	62	2105	7860	63478995
Liver function test abnormal	253.61	59.79	85	2082	48096	63438759
Leukopenia	217.92	59.79	86	2081	77204	63409651
Herpes zoster	212.51	59.79	86	2081	82376	63404479
Fibromyalgia	207.66	59.79	84	2083	80336	63406519
Blood cholesterol increased	198.28	59.79	85	2082	93947	63392908
Arthritis	178.11	59.79	84	2083	115837	63371018
Peripheral swelling	148.52	59.79	99	2068	265843	63221012
Synovitis	140.32	59.79	84	2083	186834	63300021
Infection	127.00	59.79	85	2082	229088	63257767
Oral pain	113.88	59.79	41	2126	28353	63458502
Anaemia	110.29	59.79	86	2081	293344	63193511
Joint swelling	93.72	59.79	82	2085	327584	63159271
Arteriovenous fistula occlusion	83.87	59.79	14	2153	365	63486490
Blue toe syndrome	82.88	59.79	14	2153	393	63486462
Therapeutic product effect incomplete	82.80	59.79	52	2115	125004	63361851
Tenderness	69.95	59.79	27	2140	22551	63464304

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Soft tissue disorder	237.48	44.11	45	1899	3470	79738974
Pneumonia viral	221.44	44.11	50	1894	9108	79733336
Liver function test abnormal	128.67	44.11	51	1893	64424	79678020
Fibromyalgia	125.27	44.11	50	1894	64290	79678154
Herpes zoster	116.93	44.11	53	1891	93030	79649414
Blood cholesterol increased	112.57	44.11	50	1894	83670	79658774
Leukopenia	102.65	44.11	52	1892	116461	79625983
Arthritis	97.49	44.11	50	1894	114830	79627614
Peripheral swelling	91.41	44.11	65	1879	269552	79472892
Therapeutic product effect incomplete	84.97	44.11	49	1895	141596	79600848
Synovitis	84.76	44.11	50	1894	150684	79591760
Arteriovenous fistula occlusion	83.33	44.11	14	1930	538	79741906
Blue toe syndrome	82.37	44.11	14	1930	577	79741867
Oral pain	80.67	44.11	30	1914	31768	79710676
Tenderness	69.98	44.11	25	1919	23617	79718827
Infection	65.49	44.11	51	1893	241661	79500783
Joint swelling	55.56	44.11	50	1894	288596	79453848
Soft tissue swelling	51.83	44.11	11	1933	1490	79740954
Renal pain	49.85	44.11	15	1929	8281	79734163

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04BD02	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence
FDA MoA	N0000000125	Cholinergic Muscarinic Antagonists
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:50370	parasympatholytics
CHEBI has role	CHEBI:53784	antispasmodics
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D064804	Urological Agents
FDA EPC	N0000175700	Cholinergic Muscarinic Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Dysuria	indication	49650001
Urgent desire to urinate	indication	75088002
Nocturia	indication	139394000
Suprapubic pain	indication	162053006
Urinary incontinence	indication	165232002
Urinary Tract Irritation	indication
Increased Urinary Frequency	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Paralytic ileus	contraindication	55525008	DOID:8442
Gastrointestinal hemorrhage	contraindication	74474003
Gastrointestinal obstruction	contraindication	126765001
Pyloric obstruction	contraindication	244815007
Angle-closure glaucoma	contraindication	392291006	DOID:13550

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.69	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Phosphodiesterase 4	Enzyme	P27815 Q07343 Q08493 Q08499	PDE4A_HUMAN PDE4B_HUMAN PDE4C_HUMAN PDE4D_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Phosphodiesterase 7	Enzyme	Q13946 Q9NP56	PDE7A_HUMAN PDE7B_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Phosphodiesterase 8	Enzyme	O60658 O95263	PDE8A_HUMAN PDE8B_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	4.70	DRUG MATRIX

External reference:

ID	Source
4019756	VUID
N0000147847	NUI
D00718	KEGG_DRUG
3717-88-2	SECONDARY_CAS_RN
4018018	VANDF
4019756	VANDF
C0016225	UMLSCUI
CHEBI:5088	CHEBI
HWL	PDB_CHEM_ID
CHEMBL1200875	ChEMBL_ID
CHEMBL1493	ChEMBL_ID
DB01148	DRUGBANK_ID
D005422	MESH_DESCRIPTOR_UI
3354	PUBCHEM_CID
7187	IUPHAR_LIGAND_ID
1929	INN_ID
3E74Y80MEY	UNII
11048	RXNORM
4272	MMSL
4729	MMSL
47596	MMSL
d01425	MMSL
001767	NDDF
004714	NDDF
372768002	SNOMEDCT_US
53641000	SNOMEDCT_US
87090006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FLAVOXATE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0115	TABLET, FILM COATED	100 mg	ORAL	ANDA	17 sections
Flavoxate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24658-720	TABLET	100 mg	ORAL	ANDA	17 sections
Flavoxate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42806-058	TABLET	100 mg	ORAL	ANDA	17 sections
Flavoxate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50268-324	TABLET	100 mg	ORAL	ANDA	17 sections
Flavoxate Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6326	TABLET, FILM COATED	100 mg	ORAL	ANDA	19 sections
FLAVOXATE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	68151-3826	TABLET, FILM COATED	100 mg	ORAL	ANDA	19 sections